Xeris Biopharma (NASDAQ:XERS) Insider Beth Hecht Sells 16,666 Shares of Stock

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) insider Beth Hecht sold 16,666 shares of the firm’s stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $8.03, for a total transaction of $133,827.98. Following the completion of the transaction, the insider directly owned 1,161,128 shares of the company’s stock, valued at $9,323,857.84. This represents a 1.42% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Beth Hecht also recently made the following trade(s):

• On Monday, June 1st, Beth Hecht sold 16,667 shares of Xeris Biopharma stock. The stock was sold at an average price of $6.06, for a total transaction of $101,002.02.
• On Friday, May 1st, Beth Hecht sold 16,667 shares of Xeris Biopharma stock. The stock was sold at an average price of $6.23, for a total value of $103,835.41.

Xeris Biopharma Stock Up 3.5%

XERS stock opened at $8.28 on Friday. Xeris Biopharma Holdings, Inc. has a 1-year low of $4.62 and a 1-year high of $10.08. The firm has a market capitalization of $1.43 billion, a PE ratio of 138.00 and a beta of 0.62. The business’s 50 day simple moving average is $6.56 and its 200 day simple moving average is $6.62. The company has a current ratio of 2.12, a quick ratio of 1.50 and a debt-to-equity ratio of 17.00.

Xeris Biopharma (NASDAQ:XERS) last announced its earnings results on Thursday, May 7th. The company reported $0.01 EPS for the quarter. The business had revenue of $83.13 million during the quarter, compared to the consensus estimate of $79.83 million. Xeris Biopharma had a net margin of 3.81% and a return on equity of 735.00%. As a group, research analysts anticipate that Xeris Biopharma Holdings, Inc. will post 0.12 EPS for the current year.

Institutional Trading of Xeris Biopharma

Several institutional investors have recently modified their holdings of the business. Kestra Advisory Services LLC bought a new position in Xeris Biopharma during the 4th quarter worth $25,000. KBC Group NV bought a new stake in shares of Xeris Biopharma in the 1st quarter valued at about $27,000. Caitong International Asset Management Co. Ltd increased its stake in shares of Xeris Biopharma by 9,276.3% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 7,501 shares of the company’s stock valued at $59,000 after buying an additional 7,421 shares during the period. Northwestern Mutual Wealth Management Co. increased its stake in shares of Xeris Biopharma by 179.3% in the third quarter. Northwestern Mutual Wealth Management Co. now owns 7,789 shares of the company’s stock valued at $63,000 after buying an additional 5,000 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. raised its holdings in Xeris Biopharma by 29.2% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,063 shares of the company’s stock worth $63,000 after purchasing an additional 1,820 shares during the last quarter. Institutional investors own 42.75% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have issued reports on the stock. Wall Street Zen upgraded shares of Xeris Biopharma from a “buy” rating to a “strong-buy” rating in a research report on Saturday, March 7th. Weiss Ratings cut Xeris Biopharma from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Monday, May 11th. Four research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $10.80.

About Xeris Biopharma

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.